On this page
Short answer Starting aducanumab: what to know Common questions Related questions Sources**Aducanumab-avwa injection, sold as Aduhelm, was used to treat early Alzheimer's disease, but its FDA approval was withdrawn in November 2024.**
Treatment was intended for mild cognitive impairment or mild dementia caused by Alzheimer's disease. The medicine reduced amyloid protein plaques in the brain and was given through a vein every four weeks. Treatment required MRI scans before and during use. If you are exploring treatment for memory changes, your clinician needs to evaluate the cause and discuss currently approved options.
Starting aducanumab: what to know
Common questions
What is Aducanumab-avwa Injection used for?
Aducanumab-avwa injection (Aduhelm) was used for early Alzheimer's disease, specifically mild cognitive impairment or mild dementia caused by the disease. It targeted amyloid protein plaques in the brain and was given as an infusion into a vein every four weeks. Treatment required MRI monitoring. Its FDA approval was withdrawn on November 1, 2024, so it is no longer FDA approved. If you have memory changes or previously received Aduhelm, ask your clinician about evaluation and currently approved treatment options.